Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) Enterprise Value (2016 - 2026)

Angiodynamics' Enterprise Value history spans 17 years, with the latest figure at -$37.8 million for Q1 2026.

  • For Q1 2026, Enterprise Value rose 15.53% year-over-year to -$37.8 million; the TTM value through Feb 2026 reached -$37.8 million, up 15.53%, while the annual FY2025 figure was -$55.9 million, 26.51% up from the prior year.
  • Enterprise Value reached -$37.8 million in Q1 2026 per ANGO's latest filing, up from -$41.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$23.9 million in Q1 2022 to a low of -$78.5 million in Q1 2024.
  • Average Enterprise Value over 5 years is -$46.0 million, with a median of -$44.6 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: skyrocketed 56.14% in 2022, then crashed 160.54% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$29.9 million in 2022, then crashed by 103.96% to -$60.9 million in 2023, then increased by 11.18% to -$54.1 million in 2024, then increased by 23.02% to -$41.6 million in 2025, then grew by 9.19% to -$37.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Enterprise Value are -$37.8 million (Q1 2026), -$41.6 million (Q4 2025), and -$38.8 million (Q3 2025).